Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Notorious "pharma bro" Martin Shkreli has reached a settlement that "covers all outstanding disputes" with his former biopharmaceutical company Retrophin just weeks after he sued two company directors and its ex-general counsel from prison, Retrophin said Thursday.
Terms of the settlement were not disclosed. But Retrophin issued a statement to CNBC on Thursday when asked about Shkreli having filed a notice to dismiss on Tuesday of his recent lawsuit alleging fraud by the directors and ex-counsel.
"Retrophin and Martin Shkreli have reached a settlement resolving all outstanding disputes between them," a Retrophin spokeswoman said.
"We are pleased with this outcome and remain focused on delivering life-changing therapies to people living with rare diseases. Additional information about the settlement will be provided in Retrophin's forthcoming quarterly filing."
The spokeswoman confirmed that the settlement resolves not only Shkreli's latest suit, but also a legal action that Retrophin filed against him in August 2016 alleging that he had "breached his fiduciary duty of loyalty during his tenure as the Company's Chief Executive Officer and a member of its Board of Directors."
That action was pending in arbitration after Shkreli claimed it should be handled there instead of with a federal lawsuit, as Retrophin initially had called for.
Shkreli's latest suit had accused Retrophin's chairman of the board of directors, Gary Lyons; former company CEO Stephen Aselage, who currently is a director; and the firm's former top lawyer, Margaret Valeur-Jensen, of using fraud to oust him as head of the company in 2014.
Shkreli's lawsuit, which was filed in federal court in Manhattan on May 31, had sought damages of more than $30 million.
"After starting a biopharmaceutical company from scratch and turning it into a successful enterprise worth hundreds of millions of dollars, Mr. Shkreli was unceremoniously and illegally ousted from the company at the hands of Defendants," his suit had claimed.
On Tuesday, his lawyer filed notice that Shkreli's complaint was "voluntarily dismissed, with prejudice."
That means that Shkreli would be barred from refiling a suit of the same nature against the same defendants.
Shkreli's lawyer, Edward Kang, did not immediately respond to a request for comment.
The suit had been filed within days of Shkreli, 36, being transferred to a new prison in Pennsylvania.
He is serving a seven-year sentence for securities fraud related to his two defunct hedge funds and to Retrophin, which he founded after the funds financially collapsed.
Shkreli was convicted by a jury after a trial in August 2017 of three of eight criminal counts related to his hedge funds and to Retrophin. His release bond was revoked a month later when a judge said he was a danger to the public because of his offer on Facebook of a $5,000 bounty for samples of Hillary Clinton's hair.
The medication is used to treat a parasitic infection found in pregnant women, babies and HIV patients. Turing is now known as Phoenixus.
He had served his sentence at a low-security prison in Fort Dix, New Jersey. He was transferred to a federal jail in Brooklyn, New York, and then to Pennsylvania after The Wall Street Journal reported in March that he was still helping to "call the shots" at Phoenixus with the help of a contraband cellphone at Fort Dix.